other than an institutional client; “inside information” means the significant facts which effect the change in the price of securities but has not yet been disclosed to the public and a securities
2020. 6. Authorised the Chairman of the Board of Executive Directors and/or any person authorised by the Chairman of the Board of Executive Directors to consider any change on date, time and venue
significant facts which effect the change in the price of securities but has not yet been disclosed to the public and a securities company has acquired during the course of business undertaking; “executive
SUMMARY EXECUTIVE SUMMARY 2 2017 2018 % change Q3’2018 Q4’2018 % change million Baht million Baht y-on-y million Baht million Baht q-on-q Sales and service income 31,482 36,585 16.2% 9,691 9,933 2.5% EBITDA
EXECUTIVE SUMMARY 2 Q1’2017 Q1’2018 % change Q4’2017 Q1’2018 % change million Baht million Baht y-on-y million Baht million Baht q-on-q Sales and service income 7,651 8,156 6.6% 7,762 8,156 5.1% EBITDA 2,133
63.1% of NNP. ABBREVIATION & OUR PROJECTSFINANCIAL PERFORMANCE FINANCIAL POSITION PROGRESS OF PROJECTS UNDER CONSTRUCTION EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 6M’2017 6M’2018 % change Q1’2018 Q2’2018
EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 9M’18 9M’19 change Q3’18 Q2’19 Q3’19 change change Btmn Btmn y-on-y Btmn Btmn Btmn y-on-y q-on-q Sales and service income 26,652 32,874 23.3% 9,691 10,866 11,751 21.3
EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 6M’18 6M’19 change Q2’18 Q1’19 Q2’19 change change Btmn Btmn y-on-y Btmn Btmn Btmn y-on-y q-on-q Sales and service income 16,961 21,123 24.5% 8,805 10,257 10,866 23.4
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 30 September 2017 2018 THB mm % THB mm % THB mm % Sale Revenue Revenue from selling product under Company’s trademark 1